ArticleReproductive health2025
Feasibility and acceptability of DMPA-SC self-injection in Addis Ababa, Ethiopia: a mixed-methods study.
Article in Reproductive health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepot Medroxyprogesterone Acetate (DMPA) in a prefilled auto-disabled subcutaneous injectable contraceptive (Uniject™) can be administered by community health workers and clients. Self-injection of DMPA-SC is an evidence-based practice endorsed globally by the World Health Organization and approved in several countries. The Ethiopian Ministry of Health is interested in introducing DMPA-SC self-injection to expand family planning options. This research aimed to generate information on the safety, acceptability, and feasibility of the introduction and scale-up of DMPA-SC self-injection in Ethiopia.
methodWe used mixed-method research. Four hundred women aged 18-49 interested in DMPA-SC self-injection were enrolled in the study. Participants were recruited from six public health facilities with high family planning client load in Addis Ababa. In-depth interviews were conducted with 15 family planning providers trained on self-injection and provided DMPA-SC from six public health facilities. Participants' self-injection competency was assessed using a standardized checklist at enrollment and follow-up (three months post-enrollment). Quantitative data were analyzed using descriptive statistics, and the qualitative data were analyzed using thematic analysis.
resultsSelf-injection competency among women at baseline (95%) was high and at three months follow-up (83%). Competency levels did not differ by sociodemographic characteristics. Participants reported increased confidence and comfort with self-injection during the three-month follow-up compared to baseline; 74% said they were confident to self-inject during enrollment compared with 93% at follow-up. 84% of participants said they were satisfied or very satisfied with DMPA-SC self-injection. Providers saw the benefit of offering DMPA-SC self-injection because it saves clients time, money, and the burden of having to come to a health facility. Providers suggested that DMPA-SC self-injection be added to the method mix and offered through community distribution by health extension workers.
conclusionResults showed that women can competently self-inject DMPA-SC and that it is highly acceptable to clients and providers. If made available, most women would like to continue with the method and would recommend it to others. DMPA-SC self-injection has the potential to support the Ethiopian Ministry of Health in reaching its FP2030 targets. The results from this study further support the introduction and scale-up of DMPA-SC self-injection in Ethiopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.